- Home
- NUS vs BME Comparison
NUS vs BME Comparison
Compare NUS & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- BME
- Stock Information
- Founded
- NUS 1984
- BME 2005
- Country
- NUS United States
- BME United States
- Employees
- NUS N/A
- BME N/A
- Industry
- NUS Other Pharmaceuticals
- BME Trusts Except Educational Religious and Charitable
- Sector
- NUS Health Care
- BME Finance
- Exchange
- NUS Nasdaq
- BME Nasdaq
- Market Cap
- NUS 603.4M
- BME 487.9M
- IPO Year
- NUS 1996
- BME N/A
- Fundamental
- Price
- NUS $11.22
- BME $38.03
- Analyst Decision
- NUS Hold
- BME
- Analyst Count
- NUS 2
- BME 0
- Target Price
- NUS $6.88
- BME N/A
- AVG Volume (30 Days)
- NUS 640.2K
- BME 34.0K
- Earning Date
- NUS 11-06-2025
- BME 01-01-0001
- Dividend Yield
- NUS 2.15%
- BME 6.26%
- EPS Growth
- NUS N/A
- BME N/A
- EPS
- NUS 2.03
- BME 1.44
- Revenue
- NUS $1,626,325,000.00
- BME N/A
- Revenue This Year
- NUS N/A
- BME N/A
- Revenue Next Year
- NUS $0.98
- BME N/A
- P/E Ratio
- NUS $5.50
- BME $28.37
- Revenue Growth
- NUS N/A
- BME N/A
- 52 Week Low
- NUS $5.32
- BME $35.53
- 52 Week High
- NUS $14.62
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- NUS 44.44
- BME N/A
- Support Level
- NUS $10.93
- BME N/A
- Resistance Level
- NUS $12.59
- BME N/A
- Average True Range (ATR)
- NUS 0.67
- BME 0.00
- MACD
- NUS -0.20
- BME 0.00
- Stochastic Oscillator
- NUS 7.05
- BME 0.00
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.